HBM Healthcare Investments 2022 Biotech Portfolio Overview

HBM Healthcare Investments presents its portfolio strategy in biotech and life sciences, highlighting 60-80 promising companies with focus on early-stage and mid-cap innovators. The deck covers market fundamentals, portfolio achievements including 10 IPOs and 6 trade sales in 2020, and emerging technologies such as gene editing and cell therapy. HBM demonstrates strong 5-year outperformance versus Nasdaq Biotech and MSCI World Healthcare indices.